2022
The REACH Consortium has just published the results of a multi-centre survey, aimed at assessing the uptake of Direct-acting antivirals (DAAs) for the treatment of HCV in children and adolescents living in Russia. The article is available as Open access in the Journal of Virus Eradication.
DAAs, new drugs used to treat chronic HCV, have demonstrated high rates of cure with minimal toxicity when compared to interferon-based regimens.
2017
Authors:
Published in: Pediatr Infect Dis J.